What is Accelerator?
Accelerator Life Science Partners is dedicated to fostering the development and commercialization of groundbreaking biotechnology innovations. The company provides a comprehensive suite of business, scientific, and financial resources essential for establishing and operating early-stage biotechnology ventures. By nurturing companies through all phases of development, Accelerator aims to maximize their potential for sustained success. Key resources include dedicated investment capital, experienced management teams, world-class scientific expertise, and advanced laboratory facilities. This unique ecosystem is built upon strong partnerships with leading investors, seasoned executives, and premier research institutions, enabling the transformation of novel ideas into viable commercial products and advancing the future of medicine and healthcare.
How much funding has Accelerator raised?
Accelerator has raised a total of $49.3M across 3 funding rounds:
Other Financing Round
$15M
Other Financing Round
$11.8M
Series C
$22.5M
Other Financing Round (2003): $15M with participation from ARCH Ventures
Other Financing Round (2004): $11.8M led by ARCH Ventures
Series C (2007): $22.5M supported by ARCH Ventures
Key Investors in Accelerator
ARCH Ventures
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
What's next for Accelerator?
With substantial enterprise-level funding and a recent strategic investment, Accelerator is well-positioned for accelerated growth and expansion. The company's focus on providing a complete toolkit for early-stage biotech firms suggests a strategy centered on incubating and scaling multiple ventures. Future endeavors will likely involve further strategic partnerships, continued investment in research and development infrastructure, and the expansion of its network of scientific and business advisors to support its portfolio companies in navigating the complex path to commercialization and market leadership.
See full Accelerator company page
